FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

<p>FigureS4</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Jonathan Chou (14957015) (author)
Eará dahkkit:	Emily A. Egusa (14962343) (author), Sinan Wang (14962346) (author), Michelle L. Badura (14962349) (author), Fei Lee (14962352) (author), Anil P. Bidkar (14962355) (author), Jun Zhu (14962358) (author), Tanushree Shenoy (14957003) (author), Kai Trepka (14962361) (author), Troy M. Robinson (14962364) (author), Veronica Steri (14962367) (author), Jiaoti Huang (14962370) (author), Yuzhuo Wang (14962373) (author), Eric J. Small (14962376) (author), Emily Chan (14962379) (author), Bradley A. Stohr (14962382) (author), Alan Ashworth (14957030) (author), Brant Delafontaine (14962385) (author), Sylvie Rottey (14962388) (author), Keegan S. Cooke (14962391) (author), Nooshin Hashemi Sadraei (14962394) (author), Brian Yu (14962397) (author), Mark Salvati (14962400) (author), Julie M. Bailis (14962403) (author), Felix Y. Feng (14845891) (author), Robert R. Flavell (9563200) (author), Rahul Aggarwal (14960826) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Therapeutic Research and Development Immuno-oncology Methods and Technology Drug Targets Cell surface receptor drug targets Genitourinary Cancers Prostate cancer Imaging Positron emission tomography (PET) Immunotherapy Preclinical Models Xenograft models
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

FigureS7 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

FigureS8 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

FigureS9 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

Supplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

Supplementary MovieS1b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

Supplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

Supplementary MovieS1d from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

Supplementary MovieS2a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

Supplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Dahkki: Jonathan Chou (14957015)
Almmustuhtton: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Dahkki: Xiaojiang Duan (15439264)
Almmustuhtton: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Dahkki: Xiaojiang Duan (15439264)
Almmustuhtton: (2025)

Supplementary Video S2B from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Dahkki: Xiaojiang Duan (15439264)
Almmustuhtton: (2025)

Supplementary Video S2C from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Dahkki: Xiaojiang Duan (15439264)
Almmustuhtton: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Dahkki: Yuncheng Bei (16546095)
Almmustuhtton: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Dahkki: Yuncheng Bei (16546095)
Almmustuhtton: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Dahkki: Yuncheng Bei (16546095)
Almmustuhtton: (2025)

Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Dahkki: Noor Jailkhani (16015810)
Almmustuhtton: (2025)

Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Dahkki: Noor Jailkhani (16015810)
Almmustuhtton: (2025)

Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Dahkki: Noor Jailkhani (16015810)
Almmustuhtton: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Dahkki: Steven B. Maron (15044607)
Almmustuhtton: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Dahkki: Anne-Florence Blandin (15056366)
Almmustuhtton: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Dahkki: Anne-Florence Blandin (15056366)
Almmustuhtton: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Dahkki: Anne-Florence Blandin (15056366)
Almmustuhtton: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Dahkki: Anne-Florence Blandin (15056366)
Almmustuhtton: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Dahkki: Anne-Florence Blandin (15056366)
Almmustuhtton: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Dahkki: Anne-Florence Blandin (15056366)
Almmustuhtton: (2025)

Cannot write session to /tmp/vufind_sessions/sess_i5o2ovflm7kfdnq8juq80f6fvk